Ambu stock trades higher as sales outlook lifted after Q3 jump; trims FCF forecast

Ambu A/S (AMBUb) shares rose following its Q3 results, driven by higher revenue and an upgraded full-year organic revenue growth outlook to 12-14% from 11-14%. Despite the company lowering its free cash flow forecast to DKK 400 million and reporting a quarterly decline in net profit and margins, it maintained its EBIT margin target and demonstrated strong organic growth in its Endoscopy Solutions segment and key geographical markets, signaling robust top-line momentum.

Analysis

Ambu A/S (AMBUb) presented a mixed third-quarter report, where strong top-line growth and an improved revenue outlook overshadowed significant pressure on profitability and cash flow. The company raised its full-year organic revenue growth guidance to 12-14%, reflecting robust underlying demand, which was evidenced by the quarter's 12% organic revenue increase to DKK 1.51 billion. This growth was driven by the Endoscopy Solutions division, which expanded 15.9%, and solid performance across key geographies including North America (+12.8%) and Europe (+11.5%). However, this top-line strength did not translate to the bottom line in Q3, as the EBIT margin contracted to 11.3% from 12.9% a year prior, and the gross margin fell to 58.9% due to foreign exchange and tariff costs. Consequently, quarterly net profit declined to DKK 123 million from DKK 134 million. A key concern for investors is the sharp reduction in the full-year free cash flow forecast to approximately DKK 400 million from over DKK 500 million, a move supported by the quarterly FCF decline to DKK 128 million. Despite the Q3 margin dip, management maintained its full-year EBIT margin target of 13-15%, implying a strong conviction in a fourth-quarter profitability rebound.

Key Decisions for Investors

• Investors should weigh the strong top-line momentum, evidenced by the upgraded revenue guidance, against the significant Q3 margin compression and the lowered full-year free cash flow forecast.
• Given that the company maintained its annual EBIT margin target of 13-15% despite a Q3 figure of 11.3%, Q4 performance is critical and should be monitored closely for margin recovery and any continued impact from FX and tariffs.
• The Endoscopy Solutions segment is the primary growth driver, so continued outperformance in this division is essential to support a bullish outlook, particularly as profitability headwinds persist.